A Novel Approach to Molecular Cell Pathologies of Human Down Syndrome and DS-AD
A Novel Approach to Molecular Cell Pathologies of Human Down Syndrome and DS-AD
批准号:
9291367
负责人:
JEANNE Bentley LAWRENCE
金额:
$41.93万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-12 至 2022-05-31
关键词:
AffectAlzheimer&aposs DiseaseAreaBiological AssayBiologyCRISPR/Cas technologyCell Differentiation processCell LineageCell physiologyCellsCellular MorphologyCellular StructuresCellular biologyChildChromosomesChromosomes, Human, Pair 21CiliaCodeCoupledDefectDementiaDendritic SpinesDetectionDevelopmentDevelopmental Delay DisordersDevelopmental DisabilitiesDiseaseDown SyndromeEquilibriumFemaleFoundationsFutureGene ExpressionGenesGeneticGenetic TranscriptionGenomeHumanHuman PathologyImmuneIn VitroIndividualLeadMedicalMessenger RNAMethodsMicroRNAsMitochondriaMolecularMolecular ProfilingMorphologyMyeloproliferative diseaseNerve DegenerationNeural CrestNeurobiologyNeurofibrillary TanglesNeurogliaNeurologicNeuronal DifferentiationNeuronsPathologyPathway interactionsPatientsPhenotypePopulationPreclinical Drug EvaluationPresenile Alzheimer DementiaProteinsPublishingRNARNA InterferenceRegulationResearchResearch PersonnelRiskSenile PlaquesStem cellsSyndromeSystemTechnologyTestingTimeTrisomyUndifferentiatedUntranslated RNAVariantWorkX ChromosomeX Inactivationbasebeta-site APP cleaving enzyme 1cell typecellular pathologycognitive disabilitycongenital heart disorderdisease phenotypedrug developmentdrug testinggene therapygenome editinggenome-wideimprovedinduced pluripotent stem cellinsightleukemiamigrationnano-stringnerve stem cellneurodevelopmentneurogenesisnovelnovel strategiesoverexpressionpre-clinicalrelating to nervous systemresearch clinical testingsuperoxide dismutase 1therapeutic developmenttherapy developmenttooltranscriptometranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Down Syndrome (DS), or Trisomy 21, is the leading genetic cause of developmental and cognitive disability in
children. As individuals with DS live longer, we now realize most develop early-onset Alzheimer Disease (AD).
In addition, people with DS have greatly increased risk of congenital heart disease, myeloproliferative disorder
and leukemia, as well as immune and other system defects. Hence, understanding how three copies of normal
genes on chromosome 21 impacts cell expression profiles and cell phenotypes is important not only for DS,
but for conditions that afflict the non-DS population, particularly AD, perhaps the biggest medical challenge of
our time. Researchers have sought to identify the transcriptional and phenotypic changes responsible for the
various aspects of DS; however, this work is hampered by individual variation as well as the genetic complexity
and phenotypic variability of DS. Thus, there is a critical need for better ways to determine specific cellular
pathologies and gene pathways which underlie aspects of the syndrome, and to facilitate screening of drugs to
correct them. We have recently created and demonstrated such a system and, supported by compelling
preliminary results, propose to use it to “dissect” the cellular impact of Trisomy 21, on genome-wide pathways
and phenotypes, in undifferentiated pluripotent and in neural DS stem cells. We will capitalize upon this unique
system to investigate the most direct effects of Trisomy 21 on genome-wide changes in expression of specific
genes and pathways (Aim1), correlate this with specific neural cell phenotypic changes (Aim2), and ultimately
examine the contribution of specific Chr21 genes (Aim 3) to DS and AD pathology. Rather than focus on one or
more “favored” aspects or hypotheses, we propose an unbiased and broad approach, supported by several
collaborators who are leaders in their areas of molecular cell biology and neurobiology. This novel approach
has great promise to surmount challenges that have confounded clear understanding of the basic biology of
DS, and thus provide the foundation for longer-term translational efforts to treat DS. Greater understanding of
genes and cell pathways perturbed in human DS is important for development of drug therapies (for DS and
AD), but also has implications for the potential development of “chromosome silencing” or gene therapies.
This work also has broad basic impact for understanding genome balance, the coordinated levels of
expression for genes throughout the genome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
-
批准号:10200106
-
项目类别:
-
资助金额:$55.99万
-
财政年份:2018
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
-
批准号:9982390
-
项目类别:
-
资助金额:$56.99万
-
财政年份:2018
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
-
批准号:9789061
-
项目类别:
-
资助金额:$57.13万
-
财政年份:2018
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Translational Epigenetics with XIST: Silencing Trisomy in Human Organoid and Mouse Models of Down Syndrome
-
批准号:10438826
-
项目类别:
-
资助金额:$55.85万
-
财政年份:2018
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
A Novel Approach to Molecular Cell Pathologies of Human Down Syndrome and DS-AD
-
批准号:10178060
-
项目类别:
-
资助金额:$40.13万
-
财政年份:2017
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
RNA and Genomic Junk in Fundamental Chromosome Architecture and Regulation
-
批准号:10552441
-
项目类别:
-
资助金额:$62.84万
-
财政年份:2017
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
A Novel Approach to Molecular Cell Pathologies of Human Down Syndrome and DS-AD
-
批准号:10587752
-
项目类别:
-
资助金额:$153.77万
-
财政年份:2017
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
RNA and Genomic Junk in Fundamental Chromosome Architecture and Regulation
-
批准号:10174944
-
项目类别:
-
资助金额:$59.84万
-
财政年份:2017
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Introducing Cellular Aging in Human iPS Cells to Investigate Alzheimer Pathogenesis
-
批准号:9360939
-
项目类别:
-
资助金额:$209.38万
-
财政年份:2017
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Hematopoiesis in Down Syndrome iPS cells: Correction by Chromosome 21 Silencing
-
批准号:8761875
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2014
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Hematopoiesis in Down Syndrome iPS cells: Correction by Chromosome 21 Silencing
-
批准号:9069836
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2014
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
The repeat genome in interphase chromosome structure and regulation
-
批准号:8563193
-
项目类别:
-
资助金额:$31.28万
-
财政年份:2013
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
The repeat genome in interphase chromosome structure and regulation
-
批准号:9039486
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2013
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Translating Dosage Compensation to Trisomy
-
批准号:8049267
-
项目类别:
-
资助金额:$250.71万
-
财政年份:2010
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Is Chromosome Therapy Possible for Down Syndrome and Other Karyotypic Imbalances?
-
批准号:7903514
-
项目类别:
-
资助金额:$12.3万
-
财政年份:2009
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Nuclear and Chromatin Packaging of Mammalian X-Chromosome
-
批准号:7910951
-
项目类别:
-
资助金额:$12.31万
-
财政年份:2009
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Is Chromosome Therapy Possible for Down Syndrome and Other Karyotypic Imbalances?
-
批准号:7666833
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2008
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Is Chromosome Therapy Possible for Down Syndrome and Other Karyotypic Imbalances?
-
批准号:7516022
-
项目类别:
-
资助金额:$32.71万
-
财政年份:2008
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Is Chromosome Therapy Possible for Down Syndrome and Other Karyotypic Imbalances?
-
批准号:8115937
-
项目类别:
-
资助金额:$32.25万
-
财政年份:2008
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位:
Is Chromosome Therapy Possible for Down Syndrome and Other Karyotypic Imbalances?
-
批准号:7894683
-
项目类别:
-
资助金额:$32.57万
-
财政年份:2008
-
负责人:JEANNE Bentley LAWRENCE
-
依托单位: